Banner Publications MH200828 N141

Publications

Results found: 172

Showing results: 1 - 50

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023
Key
Nature

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.

01-10-2019
Key
Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018
Key
Acta oncologica (Stockholm, Sweden)

The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP).

23-05-2024
Acta oncologica (Stockholm, Sweden)

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.

23-05-2024
Scientific reports

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.

16-05-2024
The Journal of pathology

Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.

15-05-2024
The oncologist

Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.

03-05-2024
European journal of cancer (Oxford, England : 1990)

Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).

01-05-2024
Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-05-2024
Cancer treatment reviews

Agnostic drug development revisited.

27-04-2024
Cell

A pan-cancer analysis of the microbiome in metastatic cancer.

25-04-2024
Clinical cancer research : an official journal of the American Association for Cancer Research

Efficacy of pembrolizumab and biomarker analysis in patients with WGS-based intermediate to high tumor mutational load: results from the Drug Rediscovery Protocol.

17-04-2024
Cancer discovery

Novel WRN Helicase Inhibitors Selectively Target Microsatellite Unstable Cancer Cells.

09-04-2024
Clinical cancer research : an official journal of the American Association for Cancer Research

Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

01-04-2024
Cell

Generating and using real-world data: A worthwhile uphill battle.

28-03-2024
Nature protocols

Optimized whole-genome sequencing workflow for tumor diagnostics in routine pathology practice.

01-03-2024
Genetics in medicine : official journal of the American College of Medical Genetics

Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.

01-02-2024
Nature medicine

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-02-2024
International journal of cancer

Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.

01-10-2023
Journal of internal medicine

Precision cancer medicine: Concepts, current practice, and future developments.

01-10-2023
Clinical advances in hematology & oncology : H&O

Repurposing drugs in oncology.

01-09-2023
The New England journal of medicine

Third-Line Therapy in Metastatic Colorectal Cancer.

13-07-2023
Cancer cell

Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

12-06-2023
Nature biotechnology

Identification of patient-specific CD4+ and CD8+ T cell neoantigens through HLA-unbiased genetic screens.

01-06-2023
Cancer medicine

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

01-06-2023
Nature reviews. Clinical oncology

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.

01-05-2023
ESMO open

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit.

01-04-2023
BMC cancer

Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.

04-03-2023
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors.

01-03-2023
Nature medicine

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

01-03-2023
Cancer cell

Base editing screens map mutations affecting interferon-γ signaling in cancer.

13-02-2023
Cancer cell

IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

09-01-2023
Journal of proteome research

Multiomics of Colorectal Cancer Organoids Reveals Putative Mediators of Cancer Progression Resulting from SMAD4 Inactivation.

06-01-2023
ESMO open

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.

01-12-2022
The Journal of pathology

Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice.

01-10-2022
European journal of cancer (Oxford, England : 1990)

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.

01-08-2022
Cancer discovery

Can Drug Repurposing Accelerate Precision Oncology?

06-07-2022
Frontiers in medicine

A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.

02-07-2022
Cancer chemotherapy and pharmacology

Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.

01-07-2022
Cell reports. Medicine

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.

21-06-2022
Nature cancer

Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

01-05-2022
The Lancet. Oncology

The DRUG Access Protocol: access inequality and European harmonisation - Authors' reply.

01-05-2022
Nature medicine

Delivering precision oncology to patients with cancer.

01-04-2022
Clinical cancer research : an official journal of the American Association for Cancer Research

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.

01-04-2022
Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022
Nature cancer

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.

01-02-2022
The Lancet. Oncology

Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.

01-02-2022
Cancers

Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.

16-01-2022
Frontiers in medicine

Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders.

28-12-2021

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.